MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
23-year-old biospecimen CRO marks milestone with expanded capabilities for translational research, biomarker discovery, companion diagnostic development, and liquid biopsy validation across oncology and autoimmune programs
LOS ANGELES, June 2, 2026 /PRNewswire/ -- MT Group, a specialty biospecimen contract research organization (CRO) supplying clinically annotated human biospecimens to pharmaceutical, biotechnology,